
    
      All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin
      (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is
      28 days.
    
  